YIDU TECH (02158) repurchased nearly one million shares on the first trading day of the Year of the Horse in Hong Kong, and has completed 16 intensive repurchases within one month.

On February 20, YIDU TECH (02158) announced that the company repurchased 163,000 shares at a price of about 6 Hong Kong dollars per share, totaling over 970,000 Hong Kong dollars on the same day, completing the first share buyback operation after the Spring Festival. Since the start of the first repurchase of the year 2026 on January 26, the company has completed 16 repurchases in less than a month, spending nearly 68 million Hong Kong dollars, continuously demonstrating a strong belief in the intrinsic value of the company. At this moment, it is a golden window period for the development of the AI medical industry, with both policy and market driving the commercialization of the industry at an accelerated pace. Eight national departments jointly issued the "Implementation Opinions on the Development of 'Artificial Intelligence + Medical Health' Applications", specifying the establishment of a number of large clinical models by 2027, achieving full coverage of intelligent assisted diagnosis in hospitals above the second level by 2030. Various local medical insurance bureaus have released pricing guidelines for AI medical services, bridging the "research and development-implementation-pricing" business loop. On the technology side, the upgrade of large model computing power is driving the accuracy of AI image recognition to exceed 98%, and AI pharmaceutical research and development cycles are being shortened from 5-8 years to just a few months, significantly increasing clinical conversion efficiency. According to Frost & Sullivan's forecast, from 2023 to 2033, China's AI medical market will soar from 8.8 billion yuan to 315.7 billion yuan, with a compound annual growth rate of 43.1%. The frequent repurchases by YIDU TECH not only demonstrate the company's confidence in its own development, but also accurately anchor the high prosperity and broad growth space of the AI medical track.